Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 47enzalutamide 46apalutamide 36Specimen Handling 30Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 26Prednisone 25darolutamide 24Docetaxel 23Pluvicto 21abiraterone 19Radiotherapy 19Biopsy 17Leuprolide 15Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11relugolix 10gallium 68 PSMA-11 10acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10Standard of Care 10Nivolumab 10cabazitaxel 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7niraparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × golimumab × 90 days × Clear all
NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

University of Washington

Phase 2 Active not recruiting
8 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡